부산대학교 도서관

Simple Summary: Studies aimed at prediction of chemotherapeutic efficacy using patient-derived ex vivo cultures (referred to here as "functional testing") have been increasing. The present review provides information on the various types of ex vivo cultures and endpoint assays that employ a range of surrogate biomarkers of drug response. As ex vivo cultures for functional testing, two-dimensional cultures, spheroids, organoids, explants (including histoculture), microfluid-based culture, and micro-organospheres are introduced. The endpoint assays described include ATP-based bulk assay, dynamic BH3 profiling, optical metabolic imaging, fluorescence lifetime imaging microscopy, fluorescent dye-based assay, mass accumulation rate assay, live cell imaging-based assay, and immunostaining for drug-specific response biomarkers. The advantages and disadvantages of these culture systems and endpoint assays are discussed. Prediction of therapeutic outcomes is important for cancer patients in order to reduce side effects and improve the efficacy of anti-cancer drugs. Currently, the most widely accepted method for predicting the efficacy of anti-cancer drugs is gene panel testing based on next-generation sequencing. However, gene panel testing has several limitations. For example, only 10% of cancer patients are estimated to have druggable mutations, even if whole-exome sequencing is applied. Additionally, even if optimal drugs are selected, a significant proportion of patients derive no benefit from the indicated drug treatment. Furthermore, most of the anti-cancer drugs selected by gene panel testing are molecularly targeted drugs, and the efficacies of cytotoxic drugs remain difficult to predict. Apart from gene panel testing, attempts to predict chemotherapeutic efficacy using ex vivo cultures from cancer patients have been increasing. Several groups have retrospectively demonstrated correlations between ex vivo drug sensitivity and clinical outcome. For ex vivo culture, surgically resected tumor tissue is the most abundant source. However, patients with recurrent or metastatic tumors do not usually undergo surgery, and chemotherapy may be the only option for those with inoperable tumors. Therefore, predictive methods using small amounts of cancer tissue from diagnostic materials such as endoscopic, fine-needle aspirates, needle cores and liquid biopsies are needed. To achieve this, various types of ex vivo culture and endpoint assays using effective surrogate biomarkers of drug sensitivity have recently been developed. Here, we review the variety of ex vivo cultures and endpoint assays currently available. [ABSTRACT FROM AUTHOR]